Last reviewed · How we verify
Evolocumab Drug Substance A
Evolocumab Drug Substance A is a Small molecule drug developed by Amgen. It is currently in Phase 1 development. Also known as: AMG 145.
At a glance
| Generic name | Evolocumab Drug Substance A |
|---|---|
| Also known as | AMG 145 |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (PHASE1)
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAA (EARLY_PHASE1)
- Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial (PHASE4)
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease (PHASE2)
- Genetic Testing and Motivational Counseling for FH (NA)
- Impact of Evolocumab in Cardiac Transplant Patients With CAV (PHASE2)
- In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
- Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evolocumab Drug Substance A CI brief — competitive landscape report
- Evolocumab Drug Substance A updates RSS · CI watch RSS
- Amgen portfolio CI
Frequently asked questions about Evolocumab Drug Substance A
What is Evolocumab Drug Substance A?
Evolocumab Drug Substance A is a Small molecule drug developed by Amgen.
Who makes Evolocumab Drug Substance A?
Evolocumab Drug Substance A is developed by Amgen (see full Amgen pipeline at /company/amgen).
Is Evolocumab Drug Substance A also known as anything else?
Evolocumab Drug Substance A is also known as AMG 145.
What development phase is Evolocumab Drug Substance A in?
Evolocumab Drug Substance A is in Phase 1.
Related
- Manufacturer: Amgen — full pipeline
- Also known as: AMG 145
- Compare: Evolocumab Drug Substance A vs similar drugs
- Pricing: Evolocumab Drug Substance A cost, discount & access